Catherine E. Willoughby

Sobre mí

Publicaciones destacadas

• Atezolizumab plus bevacizumab: a novel breakthrough in hepatocellular carcinoma

  Autores: Castet F, Willoughby CE, Haber PK, Llovet JM .

  Referencia: Clinical Cancer Research 2021.

• Copy number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma

  Autores: Bassaganyas L, Pinyol R, Esteban-Fabró R, Torrens L, Torrecilla S, Willoughby CE, Franch-Expósito S, Vila-Casadesús M, Salaverria I, Montal R, Mazzaferro V, Camps J, Sia D, Llovet JM .

  Referencia: Clinical Cancer Research 2020.

• Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.

  Autores: Willoughby CE, Jiang Y, Thomas HD, Willmore E, Kyle S, Wittner A, Phillips N, Zhao Y, Tudhope SJ, Prendergast L, Junge G, Lourenco LM, Finlay MRV, Turner P, Munck JM, Griffin RJ, Rennison T, Pickles J, Cano C, Newell DR, Reeves HL, Ryan AJ, Wedge SR .

  Referencia: Journal Of Clinical Investigation 2020.

• Neutrophils - driving progression and poor prognosis in hepatocellular carcinoma?

  Autores: Margetts J, Ogle LF, Chan SL, Chan AWH, Chan KCA, Jamieson D, Willoughby CE, Mann DA, Wilson CL, Manas DM, Yeo W, Reeves HL .

  Referencia: British Journal Of Cancer 2018.

• Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for Hepatocellular Carcinoma?

  Autores: Ogle LF, Orr JG, Willoughby CE, Hutton C, McPherson S, Plummer R, Boddy AV, Curtin NJ, Jamieson D, Reeves HL .

  Referencia: Journal Of Hepatology 2016.

• Combination PARP and HDAC inhibition as a therapeutic strategy targeting liver cancer stem cells?

  Autores: Willoughby, Catherine E.; Reeves, Helen L.;.

  Referencia: Chin Clin Oncol 2016.

• DNA-PK-A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival

  Autores: Cornell, Liam; Munck, Joanne M.; Alsinet, Clara; Villanueva, Augusto; Ogle, Laura; Willoughby, Catherine E.; Televantou, Despina; Thomas, Huw D.; Jackson, Jennifer; Burt, Alastair D.; Newell, David; Rose, John; Manas, Derek M.; Shapiro, Geoffrey I.; Curtin, Nicola J.; Reeves, Helen L.;.

  Referencia: Clinical Cancer Research 2015.

Proyectos destacados

• PROJECT RESEARCHER: Discovery of biomarkers predictors of response and/or resistance to anti-PD1-based immune checkpoint inhibitors in advanced HCC.

  Investigador/a principal: Josep M Llovet

  Duración: 15/12/2018

• PROJECT RESEARCHER: Impact of cabozantinib alone or in combination with anti-PD1 on the immune system in HCC and assessment of the synergistic anti-tumoral effect in experimental models.

  Investigador/a principal: Josep M Llovet

  Duración: 03/12/2018 - 01/04/2020

• PROJECT RESEARCHER: HUNTER: Hepatocellular Carcinoma Expediter Network.

  Investigador/a principal: Derek Mann, Helen L Reeves, Josep M Llovet

  Duración: 01/12/2018 - 30/11/2022

• PRINCIPAL INVESTIGATOR: Post-Thesis Submission Scholarship - Preclinical modelling of hepatocellular carcinoma and novel strategies for therapeutic intervention.

  Investigador/a principal: Catherine E Willoughby

  Duración: 20/11/2017 - 20/02/2018

• LEAD INVESTIGATOR: PhD Studentship - Preclinical modelling of hepatocellular carcinoma and novel strategies for therapeutic intervention.

  Investigador/a principal: Helen Reeves, Stephen Wedge

  Duración: 01/10/2013 - 30/09/2017